The Value Creation Continuum
Advancing Asset Value Across Milestones
On the surface, your milestones may look the same as large pharma’s. But we know that you face very different questions along your journey. The answers to those questions can impact not only your product’s probability of success, but that of your overall company.
Click on the path to learn more about the questions and relevant solutions we provide along the continuum.
Pre-IND
Phase I
Phase II/III
Product Launch
Commercialization
& Lifecycle Management
Pre-IND
IND Submission
First in Human
Proof of Principle
Rare Disease Designation
Study
Initiated
Interim Analysis
In-house Database Lock
Results
Study Initiated
In-house Database Lock
Commercialization Decision
Completion
File NDA
FDA or Regulatory Approval
Managed Care Agreements and/or Pricing Announced
Guideline Adoption
Ongoing Growth and Lifecycle Management
Phase II
Phase III
Pre-IND
Pre-IND
IND Submission
First in Human
Proof of Principle
Phase I
Study
Initiated
Interim Analysis
In-house Database Lock
Results
Study Initiated
In-house Database Lock
Commercialization Decision
Completion
Phase II/III
Phase II
Phase III
FDA or Regulatory Approval
Managed Care Agreements and/or Pricing Announced
Product Launch
Guideline Adoption
Ongoing Growth and Lifecycle Management
Commercialization
& Lifecycle Management
Pre-IND
Your Challenges
How do I drive investor discussions for optimal outcomes?
How do I define and frame the value of my asset to create a differentiated value story?
Is there anything I can now do to mitigate regulatory risk and risk to my overall development path?
Our Solutions
Asset Valuation
& Due Diligence
Drug Development Strategy & Analytics
Clinical Development
Launch Strategy & Planning
Commercialization
& Lifecycle Management
LEARN MORE
about our relevant solutions
Phase I
Your Challenges
What can I do to demonstrate the value of my asset, and ultimately the valuation of my company?
What should be included in my Target Product Profile (TPP)?
Why is a Clinical Development Plan (CDP) important to investors and key stakeholders?
When should I start thinking about the specific landscape and market opportunity for my product?
Our Solutions
Asset Valuation
& Due Diligence
Drug Development Strategy & Analytics
Clinical Development
Launch Strategy & Planning
Commercialization
& Lifecycle Management
LEARN MORE
about our relevant solutions
Phase II/III
Your Challenges
How can I avoid costly protocol amendments?
What’s the best way to get sites up and running quickly?
What vendors do I need and how do I manage them?
How can I optimize my burn rate?
How can I get to my next milestone more quickly?
Should I sell, partner or take the product to market on my own?
Our Solutions
Asset Valuation
& Due Diligence
Drug Development Strategy & Analytics
Clinical Development
Launch Strategy & Planning
Commercialization
& Lifecycle Management
LEARN MORE
about our relevant solutions
Product Launch
Your Challenges
What’s the best way to take my product to market?
Where should I launch, and in what order?
How do I determine an optimal pricing and distribution strategy?
Do I have access to the right data and technology platforms to track my product’s performance?
Our Solutions
Asset Valuation
& Due Diligence
Drug Development Strategy & Analytics
Clinical Development
Launch Strategy & Planning
Commercialization
& Lifecycle Management
LEARN MORE
about our relevant solutions
Commercialization & Lifecycle Management
Your Challenges
What sales channels should I employ?
How do I reach the right prescribers?
What’s the best way to engage with patients?
Should I outsource commercial capabilities or build them in-house?
When should I start thinking about expanding product usage and labeling?
How do I ensure compliance with various regulatory agencies?
Our Solutions
Asset Valuation
& Due Diligence
Drug Development Strategy & Analytics
Clinical Development
Launch Strategy & Planning
Commercialization
& Lifecycle Management
LEARN MORE
about our relevant solutions
The Value Creation Continuum
Advancing Asset Value Across Milestones
On the surface, your milestones may look the same as large pharma’s. But we know that you face very different questions along your journey. The answers to those questions can impact not only your product’s probability of success, but that of your overall company.
Touch anywhere on the path to learn more about the questions and relevant solutions we provide along the continuum.
Pre-IND
Phase I
Phase II/III
Product Launch
Commercialization & Lifestyle Management
Pre-IND
IND Submission
First in Human,
Proof of Principle
Study
Initiated
Results
Commercialization
Decision
Managed Care Agreements and/or Pricing Announced
FDA or
Regulatory Approval
Guideline
Adoption
Online Growth
and Lifecycle Management
Commercialization
Lifecycle Management
Guideline
Adoption
Ongoing Growth and Lifecycle Management
Your Challenges
What sales channels should I employ?
How do I reach the right prescribers?
What’s the best way to engage with patients?
Should I outsource commercial capabilities or build them in-house?
When should I start thinking about expanding product usage and labeling?
How do I ensure compliance with various regulatory agencies?
Our Solutions
Asset Valuation
& Due Diligence
Drug Development Strategy & Analytics
Clinical Development
Launch Strategy
& Planning
Commercialization
& Lifecycle Management
LEARN MORE
about our relevant solutions
Product Launch
Close
Close
Product Launch
Managed Care Agreements and/or Pricing Announced
FDA or Regulatory Approval
Your Challenges
What's the best way to take my product to market?
Where should I launch, and in what order?
How do I determine an optimal pricing and distribution strategy?
Do I have access to the right data and technology platforms to track my product's performance?
Our Solutions
Asset Valuation
& Due Diligence
Drug Development Strategy & Analytics
Clinical Development
Launch Strategy
& Planning
Commercialization
& Lifecycle Management
LEARN MORE
about our relevant solutions
Commercialization
Lifecycle Management
Phase II/III
Close
Close
Phase II/III
Study Initiated
Results
Commercialization
Decision
Your Challenges
How can I avoid costly protocol amendments?
What's the best way to get sites up and running quickly?
What vendors do I need and how do I manage them?
How can I optimize my burn rate?
How can I get to my next milestone more quickly?
Should I sell, partner or take the product to market on my own?
Our Solutions
Asset Valuation
& Due Diligence
Drug Development Strategy & Analytics
Clinical Development
Launch Strategy
& Planning
Commercialization
& Lifecycle Management
LEARN MORE
about our relevant solutions
Product Launch
Phase I
Close
Close
Phase I
First in Human
Proof of Principle
Your Challenges
What can I do to demonstrate the value of my asset, and ultimately the valuation of my company?
What should be included in my Target Product Profile (TPP)?
Why is a Clinical Development Plan (CDP) important to investors and key stakeholders?
When should I start thinking about the specific landscape and market opportunity for my product?
Our Solutions
Asset Valuation
& Due Diligence
Drug Development Strategy & Analytics
Clinical Development
Launch Strategy
& Planning
Commercialization
& Lifecycle Management
LEARN MORE
about our relevant solutions
Phase II/III
Pre-IND
Close
Close
Pre-IND
Pre-IND
IND Submission
Your Challenges
How do I drive investor discussions for optimal outcomes?
How do I define and frame the value of my asset to create a differentiated value story?
Is there anything I can now do to mitigate regulatory risk and risk to my overall development path?
Our Solutions
Asset Valuation
& Due Diligence
Drug Development Strategy & Analytics
Clinical Development
Launch Strategy
& Planning
Commercialization
& Lifecycle Management
LEARN MORE
about our relevant solutions
Phase I
Close
Close